{"id":257146,"date":"2026-01-25T16:59:47","date_gmt":"2026-01-25T15:59:47","guid":{"rendered":"https:\/\/r3i.org\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\/"},"modified":"2026-03-05T17:53:19","modified_gmt":"2026-03-05T16:53:19","slug":"r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b","status":"publish","type":"page","link":"https:\/\/r3i.org\/ja\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\/","title":{"rendered":"R3i Editorials 11\/25 – \u8102\u8cea\u7814\u7a76\u306e\u6700\u524d\u7dda\uff1aAHA 2025 \u304b\u3089\u306e\u65b0\u3057\u3044\u77e5\u898b"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.27.4″ _module_preset=”35f37621-1062-4ae6-955d-76a3167a2aa8″ background_image=”https:\/\/r3i.org\/wp-content\/uploads\/2024\/12\/pexels-pixabay-267582.jpg&#8221<\/a>; parallax=”on” min_height=”280.8px” min_height_tablet=”367px” min_height_phone=”262.4px” min_height_last_edited=”on|phone” height=”289px” height_tablet=”289px” height_phone=”159px” height_last_edited=”on|phone” custom_margin_tablet=”” custom_margin_phone=”-17px||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”0vw||0vw||true|false” collapsed=”on” global_colors_info=”{%22gcid-primary-color%22:%91%22quote_text_color%22,%22background_color_gradient_stops%22%93}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” custom_padding=”1px|||||” global_colors_info=”{}”]<\/p>\n

R3i\u793e\u8aac<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#FFFFFF” custom_margin=”-22px|||||” custom_margin_tablet=”-22px|||||” custom_margin_phone=”-35px||||false|false” custom_margin_last_edited=”on|phone” text_font_size_tablet=”” text_font_size_phone=”13px” text_font_size_last_edited=”on|phone” text_line_height_tablet=”” text_line_height_phone=”1.4em” text_line_height_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

R3i\u793e\u8aac\u306f\u3001R3i\u7406\u4e8b\u4f1a\u306e\u30e1\u30f3\u30d0\u30fc\u306b\u3088\u3063\u3066\u4f5c\u6210\u3055\u308c\u3001\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u306e\u6b8b\u5b58\u3068\u3044\u3046\u6c38\u7d9a\u7684\u306a\u8ab2\u984c\u3078\u306e\u5bfe\u51e6\u306b\u7126\u70b9\u3092\u5f53\u3066\u3066\u3044\u308b\u3002\u3053\u308c\u3089\u306e\u8ad6\u8aac\u306f\u3001\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u30ea\u30c3\u30c1\u30ea\u30dd\u86cb\u767d\u3084\u30ea\u30dd\u86cb\u767d(a)\u306a\u3069\u306e\u8102\u8cea\u95a2\u9023\u5371\u967a\u56e0\u5b50\u306b\u95a2\u3059\u308b\u65b0\u305f\u306a\u77e5\u898b\u3084\u6cbb\u7642\u6226\u7565\u306b\u3064\u3044\u3066\u3001\u533b\u7642\u5c02\u9580\u5bb6\u3092\u6559\u80b2\u3059\u308b\u5f79\u5272\u3092\u679c\u305f\u3057\u3066\u3044\u308b\u3002 <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.3″ _module_preset=”default” custom_margin=”-49px|||||” custom_padding=”2px||40px|||” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.4″ _module_preset=”default” border_radii=”off|13px|13px|13px|13px” border_width_all=”4px” border_color_all=”gcid-b673dc17-1b2a-464e-affa-1bf1ab41c0fd” border_width_all_tablet=”4px” border_width_all_phone=”0px” border_width_all_last_edited=”on|phone” border_color_all_tablet=”gcid-b673dc17-1b2a-464e-affa-1bf1ab41c0fd” border_color_all_phone=”gcid-b673dc17-1b2a-464e-affa-1bf1ab41c0fd” border_color_all_last_edited=”on|phone” box_shadow_style=”preset2″ global_colors_info=”{%22gcid-b673dc17-1b2a-464e-affa-1bf1ab41c0fd%22:%91%22border_color_all%22%93}”][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”14px” header_5_text_color=”gcid-4907c8d4-9eff-49de-91ce-43a2d3a729cf” header_6_text_color=”gcid-secondary-color” hover_enabled=”0″ inline_fonts=”Abyssinica SIL” global_colors_info=”{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-4907c8d4-9eff-49de-91ce-43a2d3a729cf%22:%91%22header_5_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}” sticky_enabled=”0″]<\/p>\n

November 2025<\/span><\/h5>\n
\u8102\u8cea\u7814\u7a76\u306e\u65b0\u3057\u3044\u52d5\u5411\u3068\u306f\uff1fAHA 2025\u304b\u3089\u306e\u77e5\u898b <\/h5>\n
Prof. Peter Libby<\/a>, Prof. Michel Hermans<\/a>, Prof. Pierre Amarenco<\/a>, Prof. Lale Tokg\u00f6zoglu<\/a> <\/h6>\n

2025 \u5e74\u306e American Heart Association\uff08AHA\uff09Scientific Sessions \u306f\u671f\u5f85\u3092\u88cf\u5207\u3089\u305a\uff0c\u8102\u8cea\u9818\u57df\u306b\u304a\u3051\u308b\u65b0\u305f\u306a\u30a8\u30ad\u30b5\u30a4\u30c6\u30a3\u30f3\u30b0\u306a\u30c7\u30fc\u30bf\u304c\u6570\u591a\u304f\u5831\u544a\u3055\u308c\u305f\u3002\u305d\u306e\u4e3b\u5f79\u306e\u4e00\u3064\u304c\uff0cPCSK9 \u963b\u5bb3\u85ac evolocumab \u3092\u7528\u3044\u305f VESALIUS-CV<\/a> \u8a66\u9a13 (1) \u3067\u3042\u308a\uff0c\u521d\u56de\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u3092\u307e\u3060\u7d4c\u9a13\u3057\u3066\u3044\u306a\u3044\u9ad8\u30ea\u30b9\u30af\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u30e9\u30f3\u30c9\u30de\u30fc\u30af\u8a66\u9a13\u3067\u3042\u308b\u3002\u30a2\u30c6\u30ed\u30fc\u30e0\u6027\u5fc3\u8840\u7ba1\u75be\u60a3\uff08ASCVD\uff09\u306f\u30ea\u30b9\u30af\u306e\u9023\u7d9a\u4f53\u3068\u3057\u3066\u6349\u3048\u3089\u308c\u3066\u304a\u308a\uff0c\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3067\u306f\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u30ea\u30b9\u30af\u306b\u5fdc\u3058\u3066\u5fc5\u8981\u306a LDL \u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\uff08LDL-C\uff09\u4f4e\u4e0b\u306e\u7a0b\u5ea6\u3092\u6c7a\u5b9a\u3059\u308b\u3053\u3068\u304c\u63a8\u5968\u3055\u308c\u3066\u3044\u308b (2,3)\u3002\u5f53\u7136\u306a\u304c\u3089\uff0c\u4e3b\u8981\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\uff08MACE\uff09\u3092\u3059\u3067\u306b\u767a\u75c7\u3057\u305f\u60a3\u8005\u306f\u6700\u3082\u9ad8\u30ea\u30b9\u30af\u3067\u3042\u308a\uff0c\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u63a8\u5968 LDL-C \u76ee\u6a19\u5024\u3092\u9054\u6210\u3059\u308b\u306b\u306f\uff0c\u901a\u5e38\uff0c\u5f93\u6765\u306e\u8102\u8cea\u4f4e\u4e0b\u7642\u6cd5\uff08\u30b9\u30bf\u30c1\u30f3\uff0b\u30a8\u30bc\u30c1\u30df\u30d6\uff09\u306b PCSK9 \u963b\u5bb3\u85ac\u3092\u8ffd\u52a0\u3059\u308b\u5fc5\u8981\u304c\u3042\u308b (2,3)\u3002\u4e00\u65b9\uff0c\u9ad8\u30ea\u30b9\u30af\u3068\u307f\u306a\u3055\u308c\u308b\u4ed6\u306e\u60a3\u8005\u96c6\u56e3\uff0c\u4f8b\u3048\u3070\u9ad8\u30ea\u30b9\u30af\u306e cardiovascular\u2013kidney\u2013metabolic syndrome\uff08\u5fc3\u8840\u7ba1\u2013\u814e\u2013\u4ee3\u8b1d\u75c7\u5019\u7fa4\uff09\u3092\u6709\u3059\u308b\u60a3\u8005 (4) \u3067\u306f\uff0cLDL-C \u4f4e\u4e0b\u7642\u6cd5\u5f37\u5316\u3092\u652f\u6301\u3059\u308b\u30a8\u30d3\u30c7\u30f3\u30b9\u306f\uff0c\u76f8\u5bfe\u7684\u306b\u4e4f\u3057\u3044\u3002 <\/p>\n

VESALIUS-CV \u306b\u306f\uff0c\u30a2\u30c6\u30ed\u30fc\u30e0\u6027\u52d5\u8108\u786c\u5316\u307e\u305f\u306f\u9ad8\u30ea\u30b9\u30af\u7cd6\u5c3f\u75c5\u3092\u6709\u3059\u308b\u304c\uff0c\u3053\u308c\u307e\u3067\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u3092\u7d4c\u9a13\u3057\u3066\u3044\u306a\u3044 12,000 \u4f8b\u8d85\u306e\u60a3\u8005\u304c\u7d44\u307f\u5165\u308c\u3089\u308c\u305f\u3002\u672c\u8a66\u9a13\u306f\uff0cLDL-C \u3092\u4e2d\u592e\u5024 45 mg\/dL \u307e\u3067\u4f4e\u4e0b\u3055\u305b\u308b\u3053\u3068\uff08\u3053\u308c\u306f\uff0c\u6b27\u5dde\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u304c\u300c\u8d85\u9ad8\u30ea\u30b9\u30af\u300d\u60a3\u8005\u306b\u63a8\u5968\u3059\u308b LDL-C <40 mg\/dL \u306e\u76ee\u6a19\u5024\u306b\u8fd1\u3044\u6c34\u6e96\u3067\u3042\u308b\uff09(3) \u306b\u3088\u308a\uff0c\u51a0\u52d5\u8108\u75be\u60a3\u6b7b\uff08CHD \u6b7b\uff09\uff0c\u5fc3\u7b4b\u6897\u585e\uff08MI\uff09\uff0c\u865a\u8840\u6027\u8133\u5352\u4e2d\u304b\u3089\u6210\u308b 3 \u70b9 MACE \u3092 25\uff05\uff0c\u865a\u8840\u99c6\u52d5\u306e\u52d5\u8108\u8840\u884c\u518d\u5efa\u8853\u3092\u52a0\u3048\u305f 4 \u70b9 MACE \u3092 19\uff05\uff0c\u3055\u3089\u306b\u521d\u56de MI \u3092 36\uff05\u4f4e\u4e0b\u3055\u305b\u308b\u3053\u3068\u3092\u660e\u78ba\u306b\u793a\u3057\u305f (1)\u3002CHD \u6b7b\u306f 11\uff05 \u6e1b\u5c11\u3057\u305f\u3082\u306e\u306e\uff0c\u30a4\u30d9\u30f3\u30c8\u6570\u304c\u5c11\u306a\u304b\u3063\u305f\u305f\u3081\u7d71\u8a08\u5b66\u7684\u6709\u610f\u5dee\u306b\u306f\u81f3\u3089\u305a\uff0c\u305d\u306e\u7d50\u679c\u3068\u3057\u3066\u4ed6\u306e\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u306b\u5bfe\u3059\u308b\u691c\u5b9a\u306f\u884c\u308f\u308c\u306a\u304b\u3063\u305f\u3002\u3057\u304b\u3057\uff0c\u5fc3\u8840\u7ba1\u6b7b\u4ea1 21\uff05\u6e1b\u5c11\uff0c\u5168\u6b7b\u4ea1 20\uff05\u6e1b\u5c11\uff0c\u865a\u8840\u6027\u8133\u5352\u4e2d 21\uff05\u6e1b\u5c11\u3068\u3044\u3046\u6240\u898b\u306f\u3044\u305a\u308c\u3082\u81e8\u5e8a\u7684\u306b\u304d\u308f\u3081\u3066\u610f\u5473\u306e\u3042\u308b\u7d50\u679c\u3067\u3042\u308b (1)\u3002\u3053\u308c\u3089\u3092\u7dcf\u5408\u3059\u308b\u3068\uff0cVESALIUS-CV \u306e\u7d50\u679c\u306f\uff0c\u300cLDL-C \u3092\u3088\u308a\u4f4e\u304f\u3059\u308c\u3070\u3059\u308b\u307b\u3069\u81e8\u5e8a\u30a2\u30a6\u30c8\u30ab\u30e0\u306f\u826f\u597d\u306b\u306a\u308b\u300d\u3068\u3044\u3046\u6982\u5ff5\u3092\u6539\u3081\u3066\u5f37\u304f\u652f\u6301\u3057\u3066\u3044\u308b (5)\u3002\u4e00\u65b9\u3067\uff0c\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u306e\u5b9f\u88c5\u306f\u4f9d\u7136\u3068\u3057\u3066\u5927\u304d\u306a\u8ab2\u984c\u3067\u3042\u308b\u3002\u4e16\u754c\u898f\u6a21\u306e\u5b9f\u81e8\u5e8a\u30c7\u30fc\u30bf\u3067\u3042\u308b VESALIUS-REAL \u3067\u306f\uff0cVESALIUS-CV \u3068\u540c\u69d8\u306e\u7279\u5fb4\u3092\u6709\u3059\u308b\u60a3\u8005\u306e 82\uff05 \u304c\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u63a8\u5968\u306e LDL-C \u76ee\u6a19\u5024\u306b\u5230\u9054\u3057\u3066\u3044\u306a\u304b\u3063\u305f\u3053\u3068\u304c\u793a\u3055\u308c\u305f (6)\u3002\u6700\u5584\u306e\u8a3a\u7642\u3092\u5b9f\u73fe\u3059\u308b\u305f\u3081\u306b\u306f\uff0c\u660e\u3089\u304b\u306b\u3055\u3089\u306a\u308b\u6539\u5584\u304c\u5fc5\u8981\u3067\u3042\u308b\u3002\u307e\u305f\uff0c\u88dc\u8db3\u7684\u3067\u306f\u3042\u308b\u304c\uff0c\u7d4c\u53e3 PCSK9<\/a> \u963b\u5bb3\u85ac enlicitide \u306e\u767b\u5834\u306b\u3082\u6ce8\u76ee\u3059\u3079\u304d\u3067\u3042\u308b\u3002CORALreef Lipids \u8a66\u9a13\u3067\u306f\uff0cenlicitide \u304c\u6700\u5927 60\uff05 \u306b\u53ca\u3076\u6301\u7d9a\u7684\u306a LDL-C \u4f4e\u4e0b\u3092\u9054\u6210\u3057\u3066\u304a\u308a (7)\uff0cLDL-C \u76ee\u6a19\u9054\u6210\u306b\u5411\u3051\u305f\u5b9f\u52d9\u7684\u306a\u5229\u70b9\u3092\u3082\u305f\u3089\u3059\u53ef\u80fd\u6027\u304c\u3042\u308b\u3002 <\/p>\n

LDL-C \u3092\u8d85\u3048\u305f\u9818\u57df\u3068\u3057\u3066\uff0c\u65b0\u898f\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u4f4e\u4e0b\u7642\u6cd5\u306b\u95a2\u3059\u308b\u30c7\u30fc\u30bf\u3082\u5831\u544a\u3055\u308c\u305f\u3002\u91cd\u5ea6\u9ad8\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u8840\u75c7\u3092\u5bfe\u8c61\u3068\u3057\u305f CORE \u8a66\u9a13\uff08CORE-TIMI 72a \u304a\u3088\u3073 CORE2-TIMI 72b\uff0c\u60a3\u8005\u6570 1,000 \u4f8b\u8d85\uff09\u3067\u306f\uff0c\u30a2\u30dd\u30ea\u30dd\u86cb\u767d CIII\uff08APOC3\uff09 <\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”gcid-4907c8d4-9eff-49de-91ce-43a2d3a729cf” text_font_size=”14px” global_colors_info=”{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-4907c8d4-9eff-49de-91ce-43a2d3a729cf%22:%91%22text_text_color%22%93}”]<\/p>\n

\u3092\u6a19\u7684\u3068\u3059\u308b\u30a2\u30f3\u30c1\u30bb\u30f3\u30b9\u30aa\u30ea\u30b4\u30cc\u30af\u30ec\u30aa\u30c1\u30c9 olezarsen\uff08\u6708 1 \u56de 50 mg \u307e\u305f\u306f 80 mg \u6295\u4e0e\uff09\u306b\u3088\u308a\uff0c\u8840\u6f3f\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u5024\u304c\u9855\u8457\u304b\u3064\u6301\u7d9a\u7684\u306b\u4f4e\u4e0b\u3059\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f (8)\u300212 \u304b\u6708\u6642\u70b9\u3067\uff0c\u3044\u305a\u308c\u306e olezarsen \u6295\u4e0e\u7fa4\u306b\u304a\u3044\u3066\u3082 86\uff05 \u306e\u60a3\u8005\u304c\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9 500 mg\/dL \u672a\u6e80\u3092\u9054\u6210\u3057\uff0c\u3055\u3089\u306b 1\/3\u301c1\/2 \u306e\u60a3\u8005\u304c 150 mg\/dL\uff081.69 mmol\/L\uff09\u672a\u6e80\u307e\u3067\u4f4e\u4e0b\u3057\u305f\u3002\u52a0\u3048\u3066\uff0colezarsen \u306e\u30d7\u30fc\u30eb\u89e3\u6790\u3067\u306f\uff0c\u30d7\u30e9\u30bb\u30dc\u3068\u6bd4\u8f03\u3057\u3066\u6025\u6027\u81b5\u708e\u767a\u75c7\u7387\u304c 85\uff05 \u6e1b\u5c11\u3057\uff0c1 \u5e74\u9593\u306b\u6025\u6027\u81b5\u708e 1 \u4f8b\u3092\u4e88\u9632\u3059\u308b\u305f\u3081\u306b\u5fc5\u8981\u306a\u6cbb\u7642\u4eba\u6570\uff08NNT\uff09\u306f 20 \u3068\u7b97\u51fa\u3055\u308c\u305f (8)\u3002\u91cd\u5ea6\u9ad8\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u8840\u75c7\u3067\u691c\u8a0e\u3055\u308c\u305f\u3082\u3046\u4e00\u3064\u306e\u85ac\u5264\u304c DR10624 \u3067\u3042\u308b\u3002\u3053\u308c\u306f\uff0cFGF21\uff08Fibroblast Growth Factor 21\uff09\uff0c\u30b0\u30eb\u30ab\u30b4\u30f3\uff0c\u30b0\u30eb\u30ab\u30b4\u30f3\u69d8\u30da\u30d7\u30c1\u30c9-1\uff08GLP-1\uff09\u53d7\u5bb9\u4f53\u3092\u540c\u6642\u306b\u6a19\u7684\u3068\u3059\u308b\uff0c\u521d\u306e\u4e09\u91cd\u4f5c\u52d5\u85ac\u3067\u3042\u308b\u3002\u60a3\u8005\u6570\u304c\u5c11\u306a\u304f\uff0c\u307b\u307c\u5168\u4f8b\u304c\u6f22\u6c11\u65cf\u306e\u4e2d\u56fd\u4eba\u3067\u3042\u308b\u3053\u3068\u306b\u52a0\u3048\uff0c\u6cbb\u7642\u671f\u9593\u3082\u77ed\u3044\u3068\u3044\u3046\u5236\u7d04\u306f\u3042\u308b\u3082\u306e\u306e\uff0c12 \u9031\u6642\u70b9\u3067\u7d04 70\uff05 \u4ee5\u4e0a\u306e\u8840\u6f3f\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u4f4e\u4e0b\u304c\u8a8d\u3081\u3089\u308c\uff0c\u672c\u85ac\u306b\u3088\u308b\u65b0\u898f\u6cbb\u7642\u30a2\u30d7\u30ed\u30fc\u30c1\u306e\u6709\u671b\u6027\u304c\u793a\u5506\u3055\u308c\u305f (9)\u3002\u3053\u308c\u3089\u306e\u6240\u898b\u306f\uff0c\u5f93\u6765\u306e\u6cbb\u7642\uff08\u30d5\u30a3\u30d6\u30e9\u30fc\u30c8\uff0c\u9ad8\u7528\u91cf\u30aa\u30e1\u30ac 3 \u8102\u80aa\u9178\uff0c\u30b9\u30bf\u30c1\u30f3\u306a\u3069\uff09\u304c\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u4f4e\u4e0b\u52b9\u679c\u306b\u4e4f\u3057\u304f\uff0c\u81b5\u708e\u30ea\u30b9\u30af\u4f4e\u6e1b\u52b9\u679c\u3082\u8a8d\u3081\u3089\u308c\u3066\u3044\u306a\u3044\u3068\u3044\u3046\u80cc\u666f (10) \u3092\u8e0f\u307e\u3048\u308b\u3068\uff0c\u91cd\u5ea6\u9ad8\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u8840\u75c7\u60a3\u8005\u306e\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u306b\u65b0\u305f\u306a\u5e0c\u671b\u3092\u3082\u305f\u3089\u3059\u3002 <\/p>\n

\u3092\u6a19\u7684\u3068\u3059\u308b\u30a2\u30f3\u30c1\u30bb\u30f3\u30b9\u30aa\u30ea\u30b4\u30cc\u30af\u30ec\u30aa\u30c1\u30c9 olezarsen\uff08\u6708 1 \u56de 50 mg \u307e\u305f\u306f 80 mg \u6295\u4e0e\uff09\u306b\u3088\u308a\uff0c\u8840\u6f3f\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u5024\u304c\u9855\u8457\u304b\u3064\u6301\u7d9a\u7684\u306b\u4f4e\u4e0b\u3059\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f (8)\u300212 \u304b\u6708\u6642\u70b9\u3067\uff0c\u3044\u305a\u308c\u306e olezarsen \u6295\u4e0e\u7fa4\u306b\u304a\u3044\u3066\u3082 86\uff05 \u306e\u60a3\u8005\u304c\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9 500 mg\/dL \u672a\u6e80\u3092\u9054\u6210\u3057\uff0c\u3055\u3089\u306b 1\/3\u301c1\/2 \u306e\u60a3\u8005\u304c 150 mg\/dL\uff081.69 mmol\/L\uff09\u672a\u6e80\u307e\u3067\u4f4e\u4e0b\u3057\u305f\u3002\u52a0\u3048\u3066\uff0colezarsen \u306e\u30d7\u30fc\u30eb\u89e3\u6790\u3067\u306f\uff0c\u30d7\u30e9\u30bb\u30dc\u3068\u6bd4\u8f03\u3057\u3066\u6025\u6027\u81b5\u708e\u767a\u75c7\u7387\u304c 85\uff05 \u6e1b\u5c11\u3057\uff0c1 \u5e74\u9593\u306b\u6025\u6027\u81b5\u708e 1 \u4f8b\u3092\u4e88\u9632\u3059\u308b\u305f\u3081\u306b\u5fc5\u8981\u306a\u6cbb\u7642\u4eba\u6570\uff08NNT\uff09\u306f 20 \u3068\u7b97\u51fa\u3055\u308c\u305f (8)\u3002\u91cd\u5ea6\u9ad8\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u8840\u75c7\u3067\u691c\u8a0e\u3055\u308c\u305f\u3082\u3046\u4e00\u3064\u306e\u85ac\u5264\u304c DR10624 \u3067\u3042\u308b\u3002\u3053\u308c\u306f\uff0cFGF21\uff08Fibroblast Growth Factor 21\uff09\uff0c\u30b0\u30eb\u30ab\u30b4\u30f3\uff0c\u30b0\u30eb\u30ab\u30b4\u30f3\u69d8\u30da\u30d7\u30c1\u30c9-1\uff08GLP-1\uff09\u53d7\u5bb9\u4f53\u3092\u540c\u6642\u306b\u6a19\u7684\u3068\u3059\u308b\uff0c\u521d\u306e\u4e09\u91cd\u4f5c\u52d5\u85ac\u3067\u3042\u308b\u3002\u60a3\u8005\u6570\u304c\u5c11\u306a\u304f\uff0c\u307b\u307c\u5168\u4f8b\u304c\u6f22\u6c11\u65cf\u306e\u4e2d\u56fd\u4eba\u3067\u3042\u308b\u3053\u3068\u306b\u52a0\u3048\uff0c\u6cbb\u7642\u671f\u9593\u3082\u77ed\u3044\u3068\u3044\u3046\u5236\u7d04\u306f\u3042\u308b\u3082\u306e\u306e\uff0c12 \u9031\u6642\u70b9\u3067\u7d04 70\uff05 \u4ee5\u4e0a\u306e\u8840\u6f3f\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u4f4e\u4e0b\u304c\u8a8d\u3081\u3089\u308c\uff0c\u672c\u85ac\u306b\u3088\u308b\u65b0\u898f\u6cbb\u7642\u30a2\u30d7\u30ed\u30fc\u30c1\u306e\u6709\u671b\u6027\u304c\u793a\u5506\u3055\u308c\u305f (9)\u3002\u3053\u308c\u3089\u306e\u6240\u898b\u306f\uff0c\u5f93\u6765\u306e\u6cbb\u7642\uff08\u30d5\u30a3\u30d6\u30e9\u30fc\u30c8\uff0c\u9ad8\u7528\u91cf\u30aa\u30e1\u30ac 3 \u8102\u80aa\u9178\uff0c\u30b9\u30bf\u30c1\u30f3\u306a\u3069\uff09\u304c\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u4f4e\u4e0b\u52b9\u679c\u306b\u4e4f\u3057\u304f\uff0c\u81b5\u708e\u30ea\u30b9\u30af\u4f4e\u6e1b\u52b9\u679c\u3082\u8a8d\u3081\u3089\u308c\u3066\u3044\u306a\u3044\u3068\u3044\u3046\u80cc\u666f (10) \u3092\u8e0f\u307e\u3048\u308b\u3068\uff0c\u91cd\u5ea6\u9ad8\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u8840\u75c7\u60a3\u8005\u306e\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u306b\u65b0\u305f\u306a\u5e0c\u671b\u3092\u3082\u305f\u3089\u3059\u3002 <\/p>\n

CTX310<\/a> \u306f\uff0cCRISPR-Cas9\uff08clustered regularly interspaced short palindromic repeats\u2013Cas9 endonuclease\uff09\u6280\u8853\u3092\u7528\u3044\u3066\u958b\u767a\u3055\u308c\u305f\u3002\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u4e0d\u826f\u306e\u9ad8\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u8840\u75c7\uff0c\u9ad8\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u8840\u75c7\uff0c\u307e\u305f\u306f\u6df7\u5408\u578b\u8102\u8cea\u7570\u5e38\u75c7\u3092\u6709\u3059\u308b\u6210\u4eba 15 \u4f8b\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2c I \u76f8\u8a66\u9a13\u3067\u306f\uff0c\u5b89\u5168\u6027\u304c\u4e3b\u305f\u308b\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u3063\u305f\u3002CTX310\uff080.1\uff0c0.3\uff0c0.6\uff0c0.7\uff0c0.8 mg\/kg\uff09\u306e\u5358\u56de\u9759\u8108\u5185\u6295\u4e0e\u306f\uff0c\u6709\u5bb3\u4e8b\u8c61\u304c\u5c11\u306a\u304f\uff0c2 \u3064\u306e\u6700\u9ad8\u7528\u91cf\u7fa4\u3067\u306f ANGPTL3 \u30ec\u30d9\u30eb\u304c 70\uff05 \u8d85\u4f4e\u4e0b\u3057\u305f\u3002\u3055\u3089\u306b\u672c\u6cbb\u7642\u306b\u3088\u308a\uff0c\u6700\u9ad8\u7528\u91cf\u3067\u306f LDL-C \u3068\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u304c\u3068\u3082\u306b\u6700\u5927 60\uff05 \u4f4e\u4e0b\u3057\u305f (11)\u3002\u5f53\u7136\u306a\u304c\u3089\uff0c\u9577\u671f\u7684\u306a\u5b89\u5168\u6027\u306f\u5927\u304d\u306a\u61f8\u5ff5\u4e8b\u9805\u3067\u3042\u308a\uff0cFDA \u306e\u8981\u4ef6\u306b\u5f93\u3063\u3066\u6700\u5927 15 \u5e74\u9593\u306e\u5b89\u5168\u6027\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u304c\u7d99\u7d9a\u3055\u308c\u3066\u3044\u308b\u3002\u3068\u306f\u3044\u3048\uff0c\u3053\u308c\u3089\u306e\u521d\u671f\u30c7\u30fc\u30bf\u306f\uff0c\u201conce and done\u201d \u306e\u5358\u56de\u6cbb\u7642\u304c\uff0c\u96e3\u6cbb\u6027\u8102\u8cea\u7570\u5e38\u75c7\uff0c\u9ad8\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u8840\u75c7\uff0c\u9ad8\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u8840\u75c7\u306e\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u3092\u6839\u672c\u7684\u306b\u5909\u3048\u308b\u53ef\u80fd\u6027\u3092\u79d8\u3081\u3066\u3044\u308b\u3053\u3068\u3092\u793a\u5506\u3057\u3066\u3044\u308b\u3002 <\/p>\n

\u4eca\u5e74\u3082 AHA Scientific Sessions 2025 \u306f\uff0c\u904e\u53bb\u306e\u671f\u5f85\u306b\u9055\u308f\u306c\u5185\u5bb9\u3067\u3042\u3063\u305f\u3002\u8102\u8cea\u7814\u7a76\u306e\u7269\u8a9e\u306f\uff0c\u4eca\u5f8c\u3082\u65b0\u305f\u306a\u7ae0\u3092\u91cd\u306d\u3066\u3044\u304f\u3053\u3068\u306b\u306a\u308b\u3060\u308d\u3046\u3002 <\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”8px” global_colors_info=”{}”]<\/p>\n

\u53c2\u8003\u6587\u732e<\/b><\/p>\n

    \n
  1. 1. Bohula EA, Marston NA, Bhatia AK, et al. Evolocumab in patients without a previous myocardial Infarction or stroke. N Engl J Med 2025; DOI: 10.1056\/NEJMoa2514428. \n
      \n
    1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140\u2013205. <\/li>\n
    2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139(25): e1046-e1081. <\/li>\n
    3. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 2023; 148: 1606-35. <\/li>\n
    4. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459-72. <\/li>\n
    5. Chan Q, Sakhula S, Ochs A, et al. Lipid lowering therapy use in high risk RISK ASCVD patients without prior MI or stroke \u2013 preliminary data from the VESALIUS-REAL, US. JACC 2025;185(12): Supplement A. <\/li>\n
    6. Navar AM, et al. Efficacy and safety of enlicitide, an oral PCSK9 inhibitor, for lowering LDL cholesterol in adults with or at-risk for ASCVD: the Phase 3 CORALreef Lipids Trial. American Heart Association Scientific Sessions 2025, Late-Breaking Science Abstract 4391578. <\/li>\n
    7. Marston NA, Bergmark BA, Alexander VJ, et al. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. N Engl J Med 2025; DOI: 10.1056\/NEJMoa2512761 <\/li>\n
    8. Li J et al. American Heart Association Scientific Sessions 2025, Abstract 4392939. <\/li>\n
    9. Filtz A, Parihar S, Greenberg GS, et al. New approaches to triglyceride reduction: is there any hope left? Am J Prev Cardiol 2024; 18: 100648. <\/li>\n
    10. Laffin LJ, Nicholls SJ, Scott RS, et al. Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3. N Engl J Med 2025; DOI: 10.1056\/NEJMoa2511778. <\/li>\n
    11. First in vivo base editing lowers cholesterol. Nat Biotechnol 2023;41:1665. <\/li>\n<\/ol>\n

       <\/p>\n

      Key words: AHA Scientific Sessions 2025; triglycerides; low-density lipoprotein cholesterol; VESALIUS-CV; olarsarzen; CTX310; gene-editing<\/em><\/p>\n<\/li>\n<\/ol>\n

        \n
      1. \n<\/li>\n<\/ol>\n

        [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

        R3i\u793e\u8aacR3i\u793e\u8aac\u306f\u3001R3i\u7406\u4e8b\u4f1a\u306e\u30e1\u30f3\u30d0\u30fc\u306b\u3088\u3063\u3066\u4f5c\u6210\u3055\u308c\u3001\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u306e\u6b8b\u5b58\u3068\u3044\u3046\u6c38\u7d9a\u7684\u306a\u8ab2\u984c\u3078\u306e\u5bfe\u51e6\u306b […]<\/p>\n","protected":false},"author":258497325,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_wpcom_ai_launchpad_about_page":false,"_wpcom_ai_launchpad_gallery_page":false,"_wpcom_ai_launchpad_contact_page":false,"_wpcom_ai_launchpad_events_page":false,"_wpcom_ai_launchpad_video_page":false,"_wpcom_ai_launchpad_portfolio_piece":false,"footnotes":""},"class_list":["post-257146","page","type-page","status-publish","hentry"],"yoast_head":"\nAHA 2025 Lipid Research: Key Insights from VESALIUS-CV & More - R3i<\/title>\n<meta name=\"description\" content=\"Highlights from AHA 2025: VESALIUS-CV outcomes with evolocumab, real-world LDL-C target shortfalls (VESALIUS-REAL), and emerging TG and gene-editing therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/r3i.org\/ja\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AHA 2025 Lipid Research: Key Insights from VESALIUS-CV & More - R3i\" \/>\n<meta property=\"og:description\" content=\"Highlights from AHA 2025: VESALIUS-CV outcomes with evolocumab, real-world LDL-C target shortfalls (VESALIUS-REAL), and emerging TG and gene-editing therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/r3i.org\/ja\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\/\" \/>\n<meta property=\"og:site_name\" content=\"R3I\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T16:53:19+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data1\" content=\"5\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\\\/\",\"url\":\"https:\\\/\\\/r3i.org\\\/ja\\\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\\\/\",\"name\":\"AHA 2025 Lipid Research: Key Insights from VESALIUS-CV & More - R3i\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/#website\"},\"datePublished\":\"2026-01-25T15:59:47+00:00\",\"dateModified\":\"2026-03-05T16:53:19+00:00\",\"description\":\"Highlights from AHA 2025: VESALIUS-CV outcomes with evolocumab, real-world LDL-C target shortfalls (VESALIUS-REAL), and emerging TG and gene-editing therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/r3i.org\\\/ja\\\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/r3i.org\\\/ja\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"R3i Editorials 11\\\/25 – \u8102\u8cea\u7814\u7a76\u306e\u6700\u524d\u7dda\uff1aAHA 2025 \u304b\u3089\u306e\u65b0\u3057\u3044\u77e5\u898b\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/#website\",\"url\":\"https:\\\/\\\/r3i.org\\\/ja\\\/\",\"name\":\"R3I\",\"description\":\"Residual Risk Reduction Initiative\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/r3i.org\\\/ja\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AHA 2025 Lipid Research: Key Insights from VESALIUS-CV & More - R3i","description":"Highlights from AHA 2025: VESALIUS-CV outcomes with evolocumab, real-world LDL-C target shortfalls (VESALIUS-REAL), and emerging TG and gene-editing therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/r3i.org\/ja\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\/","og_locale":"ja_JP","og_type":"article","og_title":"AHA 2025 Lipid Research: Key Insights from VESALIUS-CV & More - R3i","og_description":"Highlights from AHA 2025: VESALIUS-CV outcomes with evolocumab, real-world LDL-C target shortfalls (VESALIUS-REAL), and emerging TG and gene-editing therapies.","og_url":"https:\/\/r3i.org\/ja\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\/","og_site_name":"R3I","article_modified_time":"2026-03-05T16:53:19+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"5\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/r3i.org\/ja\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\/","url":"https:\/\/r3i.org\/ja\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\/","name":"AHA 2025 Lipid Research: Key Insights from VESALIUS-CV & More - R3i","isPartOf":{"@id":"https:\/\/r3i.org\/ja\/#website"},"datePublished":"2026-01-25T15:59:47+00:00","dateModified":"2026-03-05T16:53:19+00:00","description":"Highlights from AHA 2025: VESALIUS-CV outcomes with evolocumab, real-world LDL-C target shortfalls (VESALIUS-REAL), and emerging TG and gene-editing therapies.","breadcrumb":{"@id":"https:\/\/r3i.org\/ja\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/r3i.org\/ja\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/r3i.org\/ja\/r3i-editorials-11-25-%e8%84%82%e8%b3%aa%e7%a0%94%e7%a9%b6%e3%81%ae%e6%9c%80%e5%89%8d%e7%b7%9a%ef%bc%9aaha-2025-%e3%81%8b%e3%82%89%e3%81%ae%e6%96%b0%e3%81%97%e3%81%84%e7%9f%a5%e8%a6%8b\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/r3i.org\/ja\/"},{"@type":"ListItem","position":2,"name":"R3i Editorials 11\/25 – \u8102\u8cea\u7814\u7a76\u306e\u6700\u524d\u7dda\uff1aAHA 2025 \u304b\u3089\u306e\u65b0\u3057\u3044\u77e5\u898b"}]},{"@type":"WebSite","@id":"https:\/\/r3i.org\/ja\/#website","url":"https:\/\/r3i.org\/ja\/","name":"R3I","description":"Residual Risk Reduction Initiative","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/r3i.org\/ja\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"}]}},"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/Pgbfv2-14Tw","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/257146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/users\/258497325"}],"replies":[{"embeddable":true,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/comments?post=257146"}],"version-history":[{"count":6,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/257146\/revisions"}],"predecessor-version":[{"id":257383,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/257146\/revisions\/257383"}],"wp:attachment":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/media?parent=257146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}